Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial

Randomized Controlled Trial

. 2014 May 1;75(9):678-85.

doi: 10.1016/j.biopsych.2013.08.010. Epub 2013 Sep 25.

Affiliations

PMID: 24074637
DOI: 10.1016/j.biopsych.2013.08.010

Randomized Controlled Trial

Chieh-Hsin Lin et al. Biol Psychiatry. 2014.

Abstract

Background: N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA coagonists by blocking their metabolism. This study examined the efficacy and safety of sodium benzoate, a D-amino acid oxidase inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD.

Methods: We conducted a randomized, double-blind, placebo-controlled trial in four major medical centers in Taiwan. Sixty patients with amnestic mild cognitive impairment or mild AD were treated with 250-750 mg/day of sodium benzoate or placebo for 24 weeks. Alzheimer's Disease Assessment Scale-cognitive subscale (the primary outcome) and global function (assessed by Clinician Interview Based Impression of Change plus Caregiver Input) were measured every 8 weeks. Additional cognition composite was measured at baseline and endpoint.

Results: Sodium benzoate produced a better improvement than placebo in Alzheimer's Disease Assessment Scale-cognitive subscale (p = .0021, .0116, and .0031 at week 16, week 24, and endpoint, respectively), additional cognition composite (p = .007 at endpoint) and Clinician Interview Based Impression of Change plus Caregiver Input (p = .015, .016, and .012 at week 16, week 24, and endpoint, respectively). Sodium benzoate was well-tolerated without evident side-effects.

Conclusions: Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. The preliminary results show promise for D-amino acid oxidase inhibition as a novel approach for early dementing processes.

Keywords: Alzheimer disease; D-amino acids oxidase (DAAO) inhibitor; N-methyl-D-aspartate; clinical trial; mild cognitive impairment; sodium benzoate.

PubMed Disclaimer

Cited by

Redox signaling and Alzheimer's disease: from pathomechanism insights to biomarker discovery and therapy strategy.
Chen YY, Wang MC, Wang YN, Hu HH, Liu QQ, Liu HJ, Zhao YY. Chen YY, et al. Biomark Res. 2020 Sep 11;8:42. doi: 10.1186/s40364-020-00218-z. eCollection 2020. Biomark Res. 2020. PMID: 32944245 Free PMC article. Review.
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial.
Lin CH, Chen PK, Wang SH, Lane HY. Lin CH, et al. JAMA Netw Open. 2021 Apr 1;4(4):e216156. doi: 10.1001/jamanetworkopen.2021.6156. JAMA Netw Open. 2021. PMID: 33881530 Free PMC article. Clinical Trial.
Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
Cummings JL, Osse AML, Kinney JW. Cummings JL, et al. Drugs. 2023 Oct;83(15):1387-1408. doi: 10.1007/s40265-023-01938-w. Epub 2023 Sep 20. Drugs. 2023. PMID: 37728864 Free PMC article. Review.
Modulating D-amino acid oxidase (DAAO) substrate specificity through facilitated solvent access.
Subramanian K, Góra A, Spruijt R, Mitusińska K, Suarez-Diez M, Martins Dos Santos V, Schaap PJ. Subramanian K, et al. PLoS One. 2018 Jun 15;13(6):e0198990. doi: 10.1371/journal.pone.0198990. eCollection 2018. PLoS One. 2018. PMID: 29906280 Free PMC article.
Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.
Fradley R, Goetghebeur P, Miller D, Burley R, Almond S, Gruart I Massó A, Delgado García JM, Zhu B, Howley E, Neill JC, Grayson B, Gaskin P, Carlton M, Gray I, Serrats J, Davies CH. Fradley R, et al. Neurochem Res. 2023 Oct;48(10):3027-3041. doi: 10.1007/s11064-023-03956-2. Epub 2023 Jun 8. Neurochem Res. 2023. PMID: 37289348 Free PMC article.

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial - PubMed (original) (raw)